The present disclosure relates to glycoprotein CD52 and fusion proteins thereof, wherein the CD52 glycoprotein has α-2,3-sialylated N-glycans, O-glycosylation and a pI of about 5 to about 6. The disclosure further relates to the preparation and purification of these proteins and their use in the suppression of effector T-cell function and/or immune response, such as in the treatment of diseases or conditions mediated by effector T-cell function.

The invention relates to new compounds that mimic Glycosaminoglycans and are able to control interaction between Glycosaminoglycans with their effector molecules. The compounds of the invention are peptides and are able to prevent or reduce the binding of at least one effector molecule with at least one glycosaminoglycan. The compounds according to the invention can be used as drug, in particular for the stimulation of the neurogenesis and more generally to treat nervous system related pathologies.

A conjugate may comprise a first component capable of binding to a therapeutic target in the eye, one or more second component(s) capable of binding to hyaluronan, and one or more third component(s) comprising hyaluronan, wherein each second component is covalently bound to the first component and non-covalently bound to a third component, a composition comprising the conjugate for use as a medicament or for use in the treatment of an eye disease and a method of treating an eye disease in a subject. Additionally, a therapeutic molecule targeted to a tissue in a patient may comprises a hyaluronic acid binding moiety and a therapeutically active agent, wherein the hyaluronic acid binding moiety comprises at least two link domains of Versican.

The present disclosure provides a pharmaceutical composition comprising an Agrin fragment or derivative thereof, and uses of the pharmaceutical composition. The present disclosure also provides method of producing the pharmaceutical composition.

Provided are compositions and methods related to improved mucins, methods of making the improved mucins, and cells and cell cultures that express glycosylated mucins. The compositions and methods provide improved cell cultures, and improved methods of producing co-expressed proteins that are distinct from the mucins.

Disclosed is a T cell receptor (TCR) fusion protein (TFP). The fusion protein comprises a TCR subunit (or referred to as a TCR unit) and an antigen recognition unit that recognizes an antigen. The antigen is GPC3 or claudin 18.2. Also disclosed is a T cell containing the fusion protein, a pharmaceutical composition and an application method of using the fusion protein or the T cell to treat diseases such as cancer. The use of TFP or T cells not only inhibits the growth of tumor cells, but also releases fewer cytokines, thereby effectively reducing the possibility of cytokine storms.

The present disclosure relates to methods and compositions related to Chimeric Antigen Receptors (“CARs”) and modifications to the framework sequences to eliminate tonic signaling. The compositions include modified binding members having a binding specificity to chondroitin sulfate proteoglycan 4 (CSPG4) and are stable when prepared as single chain antibody (scFv) and incorporated into CARs. The methods further include nucleic acid constructs for the expression of CSPG4 CARs, and the application of the CSPG4 CAR to therapeutic methods for the treatment of cancer. The present disclosure also relates to the modification of humanized framework sequences.

Provided are shear-thinning ocular hydrogel compositions that comprise 0.1 to 5.0 wt. % (e.g. 0.1 to 3.5 wt. % or 0.1 to 2.5 wt. %) of a microgel particle-forming polymer; and 0.5 to 100 mM of a monovalent and/or polyvalent metal ion salt as a cross-linking agent; dispersed in an aqueous vehicle. The hydrogel compositions have a pH within the range of 3 to 8 and the viscosity of the gel composition reduces when the gel is exposed to shear. The compositions comprise decorin. The may also comprise an antibiotic, such as gentamicin, and an anti-inflammatory steroid, such as prednisolone. The compositions are suitable for medical use in the treatment of the eye. For example, the compositions are suitable for use in the inhibition of scarring and/or the prevention or treatment of microbial keratitis.

The disclosure provides recombinant polypeptides for treating or preventing viral infection comprising an immunoglobulin Fc fragment and at least one viral receptor or fragment thereof. Also provided are RNA molecules, therapeutic compositions, and expression systems comprising such recombinant polypeptides, along with methods of preventing or treating a viral infection in a subject in need thereof, comprising administering such recombinant polypeptides to a subject or patient.

An Agrin peptide which induces proliferation of cardiomyocytes for treating a heart disease is provided.